Anti-Müllerian hormone for assessing ovarian toxicity of cancer treatment in young women: It's complicated

Cancer. 2025 Mar 1;131(5):e35774. doi: 10.1002/cncr.35774.

Kimia Sorouri^{1

2

3}, Karen Glass^{4

5

6}, Kathryn J Ruddy⁷, Ellen Warner^{5

8}, Ann H Partridge^{1

2

9}

¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
² Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts, USA.
³ Department of Obstetrics & Gynecology, University of Alberta, Edmonton, Alberta, Canada.
⁴ CreATe Fertility Centre, Toronto, Ontario, Canada.
⁵ Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
⁶ Department of Obstetrics & Gynecology, Sunnybrook Health Sciences Center, Toronto, Ontario, Canada.
⁷ Mayo Clinic, Rochester, Minnesota, USA.
⁸ Department of Medical Oncology, Sunnybrook Health Sciences Center, University of Toronto, Toronto, Ontario, Canada.
⁹ Harvard Medical School, Boston, Massachusetts, USA.

No abstract available

Keywords: anti‐Müllerian hormone; breast cancer; cancer survivorship; ovarian toxicity; young women.